Huang Jin-Xin, Yang Rui, Long Huan, Kong Jie, Shao Guo-Qiang, Xiong Fei
State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, 210009, China.
Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Mater Today Bio. 2024 Dec 24;30:101419. doi: 10.1016/j.mtbio.2024.101419. eCollection 2025 Feb.
Hepatocellular carcinoma (HCC) is a major public health threat due to its high incidence and mortality rates. Transcatheter arterial chemoembolization (TACE), the primary treatment for intermediate-to-advanced hepatocellular carcinoma (HCC), commonly utilizes embolic agents loaded with anthracycline-based cytotoxic drugs. Post-TACE, the hypoxic microenvironment in the tumor induced by embolization stimulates the formation of new blood vessels, potentially leading to revascularization and diminishing TACE's efficacy. In clinical practice, combined therapy for liver cancer using TACE and oral targeted drugs often encounters the limitation that targeted drugs cannot efficiently reach the tumor site following TACE. We have developed chondroitin sulfate microspheres (CMs) capable of encapsulating both the cytotoxic drug idarubicin (Ida) and the vascular inhibitor Lenvatinib (Len), thereby achieving a triple therapeutic effect on liver cancer: embolic starvation, drug toxicity, and efficient inhibition of neovascularization.
肝细胞癌（HCC）因其高发病率和死亡率而成为主要的公共卫生威胁。经动脉化疗栓塞术（TACE）是中晚期肝细胞癌（HCC）的主要治疗方法，通常使用负载基于蒽环类细胞毒性药物的栓塞剂。TACE术后，栓塞诱导的肿瘤缺氧微环境刺激新血管形成，可能导致血管再通并降低TACE的疗效。在临床实践中，使用TACE和口服靶向药物联合治疗肝癌时，常常遇到靶向药物在TACE后无法有效到达肿瘤部位的限制。我们已经开发出能够同时包封细胞毒性药物伊达比星（Ida）和血管抑制剂仑伐替尼（Len）的硫酸软骨素微球（CMs），从而实现对肝癌的三重治疗效果：栓塞饥饿、药物毒性和有效抑制新生血管形成。
